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Abstract
Intrauterine growth restriction (IUGR) in preterm infants increases the risk of bronchopulmonary dysplasia, characterized by
arrested alveolarization. We evaluated the impact of two different rat models (nitric oxide synthase inhibition or protein
deprivation) of IUGR on alveolarization, before, during, and at the end of this postnatal process. We studied IUGR rat pups of
dams fed either a low protein (LPD) or a normal diet throughout gestation and pups of dams treated by continuous infusion
of Nv-nitro-L-arginine methyl ester (L-NAME) or its diluent on the last four days of gestation. Morphometric parameters,
alveolar surface (Svap), mean linear intercept (MLI) and radial alveolar count (RAC) and transcriptomic analysis were
determined with special focus on genes involved in alveolarization. IUGR pups regained normal weight at day 21 in the two
treated groups. In the LPD group, Svap, MLI and RAC were not different from those of controls at day 4, but were
significantly decreased at day 21, indicating alveolarization arrest. In the L-NAME group, Svap and RAC were significantly
decreased and MLI was increased at day 4 with complete correction at day 21. In the L-NAME model, several factors involved
in alveolarization, VEGF, VEGF-R1 and –R2, MMP14, MMP16, FGFR3 and 4, FGF18 and 7, were significantly decreased at day 4
and/or day 10, while the various factors studied were not modified in the LPD group. These results demonstrate that only
maternal protein deprivation leads to sustained impairment of alveolarization in rat pups, whereas L-NAME impairs lung
development before alveolarization. Known growth factors involved in lung development do not seem to be involved in
LPD-induced alveolarization disorders, raising the question of a possible programming of altered alveolarization.
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Introduction
Bronchopulmonary dysplasia (BPD) is a chronic lung disease
affecting preterm infants and characterized by arrested alveolar-
ization in the developmental program. Lungs affected by BPD
exhibit fewer and larger alveoli and decreased pulmonary
microvascular development [1]. Several recent reports indicate
that intrauterine growth restriction (IUGR), defined as failure of
the fetus to achieve the expected weight for a given gestational age
[2], could contribute to the development of BPD [3]. Most cases of
IUGR are due to placental insufficiency, which decreases placental
and umbilical blood flow and therefore placental transfer of
glucose, essential amino acids and oxygen to the fetus [4]. IUGR is
an important health problem, responsible for an increased risk of
morbidity and perinatal mortality [4] and has long-term conse-
quences, such as metabolic syndrome, usually attributed to ‘‘fetal
programming’’. Some studies have also suggested that compro-
mised fetal growth can lead to lung dysfunction during infancy
[3,5], childhood [5,6], and adulthood [7,8]. However, the
mechanistic basis for a relationship between IUGR and BPD
and the possibility of fetal programming of lung development have
not been elucidated, as the effects of experimental models of
IUGR on lung development depend on the model studied,
especially timing, nature of the insult and species [9].
Various models affecting the quality of intrauterine environ-
ment and leading to IUGR have been developed, such as low-
protein diet (LPD), uterine artery ligation, administration of N-
omega-nitro-L-arginine methyl ester (L-NAME, a non-specific
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NO synthase inhibitor), and gestational hyperoxia or hypoxia [10].
The effects of these models on lung development have not been
previously reported. Diaz et al. in a model of IUGR induced by L-
NAME, suggested that postnatal catch-up growth may completely
correct lung development disorders present at birth in IUGR rat
pups, [11], whereas Maritz et al., inducing IUGR by umbilico-
placental embolization in sheep, showed that structural alterations
in the lung induced by IUGR were apparent at 8 weeks and still
present 2 years after birth, indicating that IUGR may result in
permanent changes [12,13].
To investigate the relationship between IUGR and alveolariza-
tion, a key feature of BPD, we studied two models of IUGR in
rodents: one induced by maternal protein restriction throughout
gestation [10,14] and the other induced by L-NAME from day 17
until the end of gestation [15]. Morphometric analysis was
performed on lung tissue from rat pups at three key time-points of
alveolar development in the rat, from postnatal day 4 (P4) to P21,
a period characterized by a sharp rise in gas exchange surface area
[16]. Alveologenesis is a highly integrated process that implies
cooperative interactions between interstitial, epithelial, and
vascular compartments of the lung involving several key control-
molecules as various transcription factors, growth factors and
matrix-remodeling enzymes [16]. To study the molecular basis of
IUGR-induced altered alveolarization in these two models, gene
expression analysis for 13 key genes involved in alveolarization and
angiogenesis was therefore performed on P10.
Our results demonstrate that only maternal protein deprivation
leads to sustained impairment of alveolarization in rat pups,
whereas L-NAME impairs lung development only before alveo-
larization, with full recovery thereafter at P21. Known factors of
lung development do not seem to be involved in IUGR-induced
alveolarization disorders in either of the two models.
Materials and Methods
Animals and diets
All experiments were carried out in compliance with INSERM
ethical rules and the recommendations of the National Research
Council’s Guide for the Care and Use of Laboratory Animals.
Experiments were designed to minimize the number of animals
needed and the discomfort during experimental procedures. On
days 4, 10 and 21, rat pups were killed by an intraperitoneal
overdose of pentobarbital sodium (70 mg/g body weight) and then
exsanguinated by aortic transection. The ‘‘Charles River Labora-
tories Ethics Committee’’ (10/17/11 and 07/28/12) approved the
low-protein diet protocol. French Ministry of Agriculture animal
use accreditation (no. 04860) has been granted to the DHURE
laboratory in Lille for experimentation with rats.
Table 1. Weight gain: at P4, P10 and P21 of rat pups in the low protein diet-induced intrauterine growth restriction group and
control.
P4 P10 P21
Control LPD Control LPD Control LPD
Weight (g) 10.661.17 7.660.74* 22.361.01 17.961.64* 47.262.15 48.462.56
Values are expressed as mean 6 SEM.
*p,0.05 between control and LPD group; two-tailed Mann-Whitney test. n = 16–20 rat pups per group.
doi:10.1371/journal.pone.0078326.t001
Table 2. Weight gain: at P4, P10 and P21 of rat pups in L-NAME-induced intrauterine growth restriction group and control.
P4 P10 P21
Control L-NAME Control L-NAME Control L-NAME
Weight (g) 10.860.47 8.660.87* 22.161.05 19.661.41* 40.964.44 45.863.9*
The significance for each bar is indicated by *p,0.05, control vs. L-NAME; two-tailed Mann-Whitney test. Values are expressed as mean 6 SEM. n = 5–10 rat pups per
group.
doi:10.1371/journal.pone.0078326.t002
Figure 1. Light microscopic appearance of the lung in control
and low protein diet rat pups at P4 (A and B), P10 (C and D),
and P21 (E and F) of postnatal life. Photographs of the alveolar
region, taken at the same magnification, are presented for each group.
doi:10.1371/journal.pone.0078326.g001
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Female Sprague Dawley rats from Charles River (l’Abresle,
France) for the LPD model and Janvier (LeGenest St Isle, France)
for the L-NAME model were mated with a male. Day 1 of
pregnancy (E1) was determined by the presence of spermatozoa in
vaginal smears. Pregnant rats were housed individually with free
access to food and water under cyclic controlled light. All dams
littered spontaneously. Day of birth was defined as P0. At P4, P10
and P21, pups were weighed before being killed and their lungs
were harvested for determination of morphometric parameters or
were frozen.
LPD-induced IUGR. Dams were randomly divided into
two groups and fed with different diets from the day of
conception until P2. A 22% protein diet was used for the
Control group, and an isocaloric 9% protein diet was used for
the LPD group [14]. Caloric deficiency in the LPD group was
compensated by carbohydrates. After birth, litters were equal-
ized to 10 pups.
L-NAME-induced IUGR. Dams were fed with normal diet
and, on day 17 of gestation, randomly assigned to receive L-
NAME or saline until the end of gestation. An Alzet osmotic pump
(Direct Corp., Palo Alto, CA) was placed subcutaneously on the
rat’s back after general anesthesia with IsofluraneH and was used
to infuse either L-NAME (SIGMA ALDRICH N5751, 98%
powder diluted to a final dilution of 50 mg/dL) or saline vehicle.
The infusion continued until the end of gestation. To avoid a
potential effect of the product delivered via breast milk, equalized
litters of 10 pups were adopted on P2 by dams free of any
treatment or pump.
Figure 2. Morphometric analysis in control and low protein diet rat pups. Sv(a,p), Mean Linear Intercept (MLI) and Radial alveolar count
(RAC) at P4, P10, and P21 were expressed as percentage of mean control value. Significance for each bar is indicated by p values, Control vs. LPD;
two-tailed Mann-Whitney test (p,0.05). N = 5 animals per group.
doi:10.1371/journal.pone.0078326.g002
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Lung analysis
Morphometry. A cannula adapted to the size of the trachea
was selected. The cannula, filled with 4% paraformaldehyde
(PFA), was inserted into the trachea and used to inflate the lungs
with PFA at a pressure of 20 cmH2O. Lungs were then kept
inflated by tracheal occlusion and lung volume was evaluated
using the fluid displacement method [17]. Lung volume was
calculated on the basis of the measured weight increase and the
specific gravity of PFA (,1 g/cm3). Five animals selected at
random from each group were studied at each time-point.
Alveolar surface density (Sv(a,p)) was determined using point
counting and mean linear intercept (MLI) methods described by
Weibel [18]. Absolute surface area (Sa) per lung was calculated by
multiplying surface density by lung volume. Radial alveolar count
(RAC) was performed according to Emery’s method [19].
Quantitative real-time PCR. mRNA expression of genes
closely associated with alveolarization i.e. PDGF-A, MMP14 and
16, FGF7 and 18 and their receptors FGFR3 and 4 and
angiogenesis i.e. Tie 1 and 2, VEGF and its receptors, VEGFR1
and 2, and adrenomedullin (ADM) were quantified at P4, P10 and
P21. Total RNA was extracted from the entire lung tissue using
RNeasy Mini RNA extraction kit (Qiagen, Chatsworth, CA).
Purified RNA was quantified using NanoDropTM Spectropho-
tometer technology (Thermo Fischer Scientific, Wilmington,
Delaware). Total RNA was converted into cDNA using 500 ng
of total RNA, Superscript III reverse transcriptase, and random
hexamer primers (Invitrogen). Real-time PCR was performed on
an ABI Prism 7000 (Applied Biosystems, Courtaboeuf, France)
using the following protocol: initial denaturation (10 min at 95uC),
then a two-step amplification program (15 s at 95uC followed by
1 min at 60uC) repeated 40 times, and finally a dissociation
process. Each reaction consisted of a cDNA equivalent of 0.5 mg of
total RNA, 12.5 ml SYBR Green PCR Master Mix and forward
and 0.9 or 0.3 mM of reverse primers in a 25 ml reaction volume.
Levels of mRNA expression were normalized to a housekeeping
gene (18 s mRNA) and expressed as relative value using the DDCt
method relative to a calibrator sample.
Primers were designed using Primer Express 3.0 (Applied
Biosystems, Foster city, CA). Primer pairs are listed in Table S1.
Statistical analysis
Multiple group comparisons were performed by Kruskal-Wallis
analysis, and two-group comparisons were performed by Mann-
Whitney U test using GraphPad Prism software (GraphPad




Body weight was significantly lower in the LPD group
compared to the control group on P4 and P10, but not on P21
with total catch-up of growth (Table 1). Body weight was also
significantly lower in the L-NAME group (Table 2) on P4 and P10
and was slightly higher than that of the control group on P21.
Morphometric analysis
Maternal LPD resulted in significantly decreased alveolarization
on P21 (Fig. 1), at the end of the process, resulting in simplified
lung structure with enlarged airspaces and fewer secondary septa,
whereas no difference was observed on P4 (Fig. 1 and Table S2).
Morphometric analysis showed a significant 30% increase of MLI
on P10 and P21 and a significant decrease of Sv(a,p) in the same
proportions, while no significant difference was observed on P4 in
the LPD group compared to controls. On P21, RAC was
decreased by 35% in the LPD group (Fig. 2).
Maternal injection of L-NAME resulted in significantly
decreased alveolarization on P4, at the beginning of the
alveolarization process, but not at P21. Lungs from animals
exposed to L-NAME exhibited enlarged alveoli on P4, but not on
P10 and P21 (Fig. 3 and Table S3). Mean linear intercept was
increased by 60% and Sv(a,p) and RAC was decreased in the same
proportion on P4, while no between-group differences were
observed thereafter (Fig. 4).
PCR results
Gene expression in LPD-induced IUGR. mRNA levels of
factors involved in alveologenesis were assessed on P4, P10 and
P21 in rat pups. FGF7, FGF18, FGFR3 and -R4, MMP14 and 16
and PDGF-A expressions were not modified in the LPD group
compared to the control group regardless of the time-points
considered (Fig. 5). mRNA levels of genes involved in angiogenesis
were assessed at the same time-points. In the LPD group, Tie 1
and 2, VEGF and its VEGFR1 and 2 receptors and adrenome-
dullin gene expressions were not modified regardless of the time-
points considered (Fig. 6).
Gene expression in L-NAME-induced IUGR. mRNA
levels of factors involved in alveologenesis and angiogenesis were
assessed on P4, P10 and P21. On P4, MMP14, MMP16, FGFR4
and PDGF expressions were significantly decreased in the L-
NAME group compared to the control group. Fibroblast growth
factor 7, FGF18, FGF-R3 and -R4 and MMP14 expressions were
significantly decreased in the L-NAME group compared to the
control group on P10. Matrix metalloprotease 14, MMP16 and
FGFR3 expressions were significantly increased on P21 in the L-
NAME group compared to the control group (Fig. 7). Expression
of VEGF, a gene involved in angiogenesis, was significantly
Figure 3. Light microscopic appearance of the lung in control
and L-NAME rat pups at P4 (A and B), P10 (C and D), and P21 (E
and F) of postnatal life. Photographs of the alveolar region, taken at
the same magnification, are presented for each group.
doi:10.1371/journal.pone.0078326.g003
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decreased in the L-NAME group compared to the control group
on P4 and P10 (Fig. 8). Moreover, on P4, the expression of VEGF
receptors, VEGF-R1 and –R2 was significantly decreased in the L-
NAME group. On P21, adrenomedullin expression was signifi-
cantly increased in the L-NAME group compared to the control
group.
Discussion
This study, comprising complete structural analysis of lung
tissue from rat pups at three key time-points of the alveolarization
process, from the start of alveolarization on day 4, to the end of
alveolarization on day 21 [16,20], demonstrated that LPD-
induced IUGR in rats induced arrested alveolarization similar to
that observed in BPD. In this model, alveolarization was normal at
the beginning of the alveolarization process, but became
progressively impaired and markedly decreased at the end of the
process. To our knowledge, this is the first study in rodents
showing progressive impairment of alveolarization induced by
conditions leading to IUGR. In contrast, the L-NAME model
appears to be inappropriate to study long-term consequences of
IUGR for lung development, as alveolarization was impaired at P4
but subsequently returned to normal by P21. This study also
demonstrates major differences between the two IUGR models in
terms of the expression of key genes known to be involved in
alveolarization and lung angiogenesis.
In the L-NAME model, morphometric analysis revealed
significant differences in alveolarization at the beginning of the
alveolarization process, on P4, with correction on P21. These
results are similar to previously published results in this model
showing decreased alveolarization on P0 with a catch-up on P7
and P14 [11]. Although a different method was used to deliver L-
Figure 4. Morphometric analysis in control and L-NAME rat pups. Sv(a,p), Mean Linear Intercept (MLI) and Radial alveolar count (RAC) in
control and L-NAME rat pups at P4, P10, and P21 were expressed as percentage of mean control value.. The significance for each time-point is
indicated by p values, control vs. L-NAME; two-tailed Mann-Whitney test (p,0.05). n = 5 animals per group.
doi:10.1371/journal.pone.0078326.g004
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NAME in our study [11], daily gavage versus subcutaneous pump,
our study confirms that, in parallel to postnatal catch-up growth,
lung development disorders present at birth in IUGR pups may be
completely corrected in this model. The L-NAME model therefore
appears to be inappropriate to evaluate the consequences of IUGR
on alveolarization. A reversible effect of L-NAME model has been
previously demonstrated: L-NAME infusion from embryonic day
(E) 14 to E18 of gestation resulted in normal fetal and placental
growth on E21. However, Neerhof showed that perfusion of L-
NAME from day 14 to 18 of gestation only resulted in normal fetal
and placental growth on P21, suggesting a reversible phenomenon
[21]. Recent studies have also failed to demonstrate any long-term
metabolic consequences in this model [15], questioning the value
of this model to study the medium-term and long-term
consequences of IUGR.
The experimental settings of the two models used in this study
clearly varied in terms of the exposure window (last 4 days of
gestation vs. throughout gestation) and the pathophysiological
cause of low birth weight (Nitric Oxide synthase inhibition vs.
malnutrition). L-NAME treatment administered at E17 to induce
IUGR in rodents was first described 20 years ago [22]. Trials of
earlier administration of L-NAME: from day 1 to day 18, resulted
in a decreased number of implantation sites, decreased litter and
placenta weights and an increased number of maternal deaths
[23]. When administered at E12, L-NAME induced fetal
resorptions and hind limb necrosis, which were not observed
when it was administered after E15 [24]. Consequently, admin-
istration of L-NAME throughout gestation induces effects other
than IUGR and, in order to induce IUGR, L-NAME treatment is
therefore classically started in the last third of gestation. Although
Figure 5. Effect of low protein diet-induced IUGR on mRNA expression of factors involved in alveolarization at day 4, 10 and 21.
Expression of PDGF, MMP14 and 16, FGF7 and 18 and their receptors FGFR3 and 4 in neonatal rat lungs. n = 9–10 per group. mRNA expression was
assessed by real-time PCR. The significance for each bar is indicated by *: p,0.05. Control vs. LPD; two-tailed Mann-Whitney test. Values are
expressed as mean 6 SEM.
doi:10.1371/journal.pone.0078326.g005
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exposure time to each treatment could explain partly the
differences observed between the 2 models, this study design
nevertheless allows comparison of the pulmonary consequences of
IUGR in pups of similar weights at P4.
Several reports suggest that LPD-induced IUGR is responsible
for long-term metabolic consequences that are not reversible, even
in adulthood: low muscle mass [25], adult-onset glucose intoler-
ance [26], adult hypertension [27], and early aging [28]. In our
study, in the LPD-induced IUGR model, all parameters quanti-
fying alveolarization on P4 were equal to those observed in the
control group, but indicated decreased alveolarization in the LPD
group at P21: MLI, which is inversely correlated with alveolariza-
tion, was equal in the 2 groups at P4 and increased in the LPD
group at P21; Sv(a,p) was identical at P4, but significantly
decreased at P21 in the LPD group; RAC exhibited the same
pattern and was also decreased at P21. Notably, LPD group pups
Figure 6. Effect of low protein diet-induced IUGR on mRNA expression of factors involved in angiogenesis at day 4, 10 and 21.
Expression of Tie 1 and 2, VEGF and its two receptors (VEGF-R1 and 2) and ADM at P10 in neonatal rat lungs. n = 9–10 per group. mRNA expression
was assessed by real-time PCR. The significance for each bar is indicated by *: p,0.05. Control vs. LPD; two-tailed Mann-Whitney test. Values are
expressed as mean 6 SEM.
doi:10.1371/journal.pone.0078326.g006
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regained normal weight at P21 and morphometric parameters can
therefore be interpreted as reflecting a real reduction of
alveolarization, independently of weight gain. In a previous study,
we observed that morphometric parameters were closely correlat-
ed with body weight and differences between groups may be
difficult to interpret when body weights are different [29]. These
results suggest an arrest or at least a marked impairment of
alveolar development. Consequently, this experimental model can
be considered to very closely fit the characteristics of BPD,
correlated with arrested alveolarization [1]. These results appear
to be discordant with those previously published in a different rat
strain with slightly different maternal diets, eg lower protein intake
in LDP and in controls [30]. These authors did not observe any
impaired alveolar development on P70, but based on a less
complete morphometric analysis than that conducted in our study
and, more surprisingly, increased alveolarization in the LPD group
at P70.
Our study also investigated whether the gene expression of
factors involved in alveolar and vascular development was affected
by IUGR. Factors involved in alveolarization have been studied by
three main approaches: 1) alveolarization study when these factors
were not expressed in KO models [31] or by specific inhibition
[32]; 2) expression of these factors during normal alveolarization
[33]; 3) changes in the expression of these factors in models of
postnatal insult leading to alveolarization disorders such as
hyperoxia or mechanical ventilation [32]. In some cases, attempts
to correct induced alveolarization disorders by administration of
these factors were investigated, but with only partial success except
for VEGF therapy [34]. Alveologenesis is a process coordinated by
multiple interactions involving paracrine mechanisms between
Figure 7. Effect of L-NAME-induced IUGR on mRNA expression of factors involved in alveolarization at day 4, 10 and 21. Expression
of PDGF, MMP14 and 16, FGF7 and 18 and their receptors FGFR3 and 4 in neonatal rat lungs. n = 4–5 rat pups per group. mRNA expression was
assessed by real-time PCR. The significance for each bar is indicated by *: p,0.05, control vs. L-NAME; two-tailed Mann-Whitney test. Values are
expressed as mean 6 SEM.
doi:10.1371/journal.pone.0078326.g007
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lung fibroblastic, epithelial, microvascular and extracellular matrix
(ECM) components [16]. The factors studied here have been
extensively described in this process. The role of antenatal events
in the pathogenesis of alveolarization disorders has been well
documented, especially in antenatal inflammation models [35].
However, alterations of factors involved in alveolarization have
been less extensively studied in models and the results are fairly
discordant. Intra-amniotic injection of group B streptococcus in
macaques induced abnormal alveolar development with altered
expressions of MMP2 and angiopoietin only [36]. Overall, the
results are fairly discordant, as factors and their modifications vary
from one model to another, highlighting the complexity of
processes in which each factor is involved at a precise timing with
precise interactions with other factors.
In the L-NAME model, factors previously shown to be involved
in alveolarization, MMP14, FGFR3 and 4, FGF18 and 7, were
significantly decreased on P4 and/or P10, but this decrease was
not associated with impaired alveolarization at P10. Interestingly,
L-NAME, given from E10 to E20 in pregnant Sprague-Dawley
rats via an osmotic pump, decreased MMP14 expression in the
uterine vessel wall on E20 [37]. Whether this effect on MMP14 is
also observed in the fetus and during the first days of life has yet to
be studied. Surprisingly, MMP14 expression was significantly
increased in the L-NAME group on P21, at a time when the
Figure 8. Effect of L-NAME-induced IUGR on mRNA expression of factors involved in angiogenesis at day 4, 10 and 21. Expression of
Tie 1 and 2, VEGF and its two receptors (VEGFR1 and 2) and ADM in neonatal rat lungs. n = 4–5 rat pups per group. mRNA expression was assessed by
real-time PCR. The significance for each bar is indicated by *: p,0.05, control vs. L-NAME; two-tailed Mann-Whitney test. Values are expressed as
mean 6 SEM.
doi:10.1371/journal.pone.0078326.g008
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alveolarization process is theoretically completed and the de-
creased alveolarization observed at P4 has been corrected much
earlier as observed in our study at P10 and in other studies at P7
[11]. Similar surprising results were observed for VEGF expres-
sion. VEGF increased during alveolarization, and decreased when
alveolarization was impaired. VEGF inhibition decreased alveo-
larization and VEGF administration restored alveolarization, even
after the end of the alveolarization process [34]. In our study,
antenatal L-NAME treatment induced a sustained decrease of
VEGF and its receptor expressions (P4 and/or P10) during the
alveolarization process and in the period during which alveolar-
ization can be assumed to have been restored in this model.
Finally, none of the factors usually described as essential for
alveolarization were modified in the LPD model. These results
raise the following question: when the alveolarization process is
impaired antenatally, does it respond to regulation factors other
than those involved in the normal process and in postnatal models
of impaired alveolarization in rat pups?
It has now been clearly established that the developing fetus
perceives the environment during specific windows of sensitivity
and optimizes future metabolic responses by reprogramming its
genome. This reprogramming promotes early survival and
reproductive success, but potentially causes a predisposition to
disease in later life [10], that only develops when an additional
stress occurs subsequently (preterm birth, obesity or high-fat diet).
The hypothesis of the fetal or ‘‘early’’ origin of adult disease was
originally proposed by Barker, who stated that environmental
factors, particularly nutrition, act in early life to program risks for
metabolic syndrome, hypertension, insulin resistance and obesity.
Lung consequences of IUGR have now also been clearly
demonstrated with an increased incidence of BPD [3] and long-
term impairment of lung function [8]. Our results suggest that a
compromised intrauterine environment could disrupt normal fetal
lung development by pathways other than those described in
classical models of altered alveolarization. When a modification of
programming occurs, involvement of growth factors is inconstant
as demonstrated for other organs in IUGR models. Microarray
analysis in LPD-induced IUGR in rat showed that only 5 of the 54
crucial factors for kidney development were significantly modified
[14]. Proteomic studies in IUGR piglets have shown that, in
addition to a significant reduction in small intestine, liver and
skeletal muscle masses, IUGR was also associated with an
alteration of proteins known to regulate cellular signalling and
intermediary metabolism, resulting in increased proteolysis and
reduced polypeptide synthesis [38]. However, the consequences on
lung development specifically related to intrauterine growth
restriction need to be more thoroughly investigated.
In conclusion, our results demonstrate that two models of
IUGR, L-NAME and LPD, have very different impacts on lung
development and gene expression patterns of key factors involved
in lung development. Only the LPD model closely fits with IUGR-
induced alveolarization disorder. The absence of involvement of
key factors of alveolarization despite abnormal lung development
raises the issue of the role of other regulators. Morbidity induced
by IUGR should be analyzed in terms of its pathophysiological
cause rather than low birth weight per se and LPD-induced IUGR
may therefore constitute a useful tool for an experimental
approach to IUGR-induced BPD.
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